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Abstract
Background: Prior studies have shown an increase in multidrug-resistant (MDR) E. coli colonization from two
percent in U.S.-based to 11 % in deployed, healthy military personnel. It is unclear if colonization with MDR
organisms occurs through deployment exposures or risks related to routine overseas travel. This study prospectively
evaluates rates and risk factors associated with MDR gram-negative bacterial and methicillin-resistant S. aureus
(MRSA) colonization after international travel.
Methods: Participants traveled internationally for five or more days. Pre- and post-travel, colonizing bacteria from
oropharyngeal, nares, groin, and peri-rectal (PR) areas were collected using BD CultureSwab™ MaxV(+). Identification
and susceptibilities were done utilizing the BD Phoenix™ Automated Microbiology System. Non-MDR pre- and post-
travel MDR bacteria within a subject were compared by pulsed-field gel electrophoresis (PFGE). A questionnaire
solicited demographics and potential risk factors for MDR acquisition.
Results: Of 58 participants, 41 % were male and median age was 64 years. Pre- and post-travel swabs were
obtained a median of ten and seven days before and after travel, respectively. Itineraries included 18 participants
traveling to the Caribbean and Central America, 17 to Asia, 16 to Africa, 5 to Europe, 4 to South and North America.
Seventeen of 22 travelers used atovaquone/proguanil for malaria prophylaxis. The only MDR organism isolated was
extended-spectrum β-lactamase (ESBL)-producing E. coli in five (9 %) participants post-travel (all PR and unrelated
by PFGE). There were no statistically significant associations between exposure risks and new ESBL-producing E.coli
colonization. Of 36 participants colonized with E. coli pre- and post-travel, new resistance was detected: TMP/SMX
in 42 % of isolates (p < 0.01), tetracycline in 44 % (p < 0.01), and ampicillin-sulbactam in 33 % (p = 0.09). No
participants were colonized with MRSA pre- or post-travel.
Conclusion: Consistent with prior studies, new antimicrobial resistance was noted in colonizing E. coli after
international travel. Nine percent of participants acquired new strains of ESBL-producing E.coli without
identified risks.
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Background
Foreign travel has been increasingly recognized as a con-
tributor to the global spread of extended-spectrum β-
lactamase (ESBL)-producing Enterobacteriaceae [1–8]. The
specific exposures during international travel that place
people at risk for acquisition of multidrug-resistant (MDR)
bacterial colonization are slowly being identified [7–9]. This
increase in ESBL-producing Enterobacteriaceae (particu-
larly E. coli) colonization has also been identified in healthy,
deployed personnel during operations in Afghanistan [10].
Whether the risks associated with these increased rates are
related to those of all international travelers or to risk fac-
tors particular to the deployed population remains to be
answered. Outside the first 24 hours following injury, in-
fections remain a leading cause of morbidity and mortality
in military combat casualties so pre-injury MDR bacterial
colonization is of particular concern for deployed
personnel [11–13]. As such, we evaluated the rates of
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MDR organism pre- and post-travel colonization within
a population of international travelers based out of San
Antonio Military Medical Center (SAMMC). The ob-
jective of this pilot study was to prospectively assess
antimicrobial resistance patterns and associated risk
factors in bacterial colonization before and after inter-
national travel in a U.S. cohort.
Methods
Study design and definitions
Study participants included active duty personnel or
Department of Defense beneficiaries ≥18 years of age
traveling internationally for five or more days and had been
seen for a pre-travel visit at SAMMC between February 1
and November 1, 2013. Exclusion criteria included ac-
tive infection at the time of enrollment (as determined
by the clinical provider), inability to complete the
culture swabs or questionnaire, or inability to attend a
post-travel visit. At pre- and post-travel visits, subjects
completed a questionnaire assessing demographics and
exposures potentially related to antimicrobial resistance
acquisition during travel including purpose, itinerary,
accommodations, water exposure, antimicrobial expo-
sures, hospitalizations, and illnesses. The study was
reviewed and conducted as per ethical standards of the
Institutional Review Board of the Brooke Army Medical
Center.
Bacterial susceptibility
At the time of enrollment and within 6 weeks of return
from travel, patients had culture swabs obtained from
the anterior nares, oropharynx, groin, and perirectal area
to determine bacterial colonization. BD CultureSwab™
MaxV(+) (Becton, Dickinson and Company, Franklin
Lakes, NJ) was used to sample all sites for detection of
bacteria. Swabs were plated onto sheep blood, MacConkey
agar, and CHROMagar™ Staph aureus in order to isolate
all gram-negative bacterial colonies and S. aureus. Col-
onies demonstrating morphology consistent with gram-
negative or S. aureus were subcultured onto sheep blood
agar in order to assure culture purity. All isolates were fro-
zen at −80 °C in Trypticase Soy Broth with 15 % glycerol.
Individual colonies underwent further automated testing
(BD Phoenix™ Automated Microbiology System-Becton
Dickinson, Franklin Lakes, NJ) for identification and anti-
microbial susceptibility testing.
Non-ESBL pre- and ESBL-producing post-travel E. coli
within a subject were compared by pulsed-field gel electro-
phoresis (PFGE) to determine genetic relatedness. The U.S.
Food and Drug Administration protocol for gram-negative
rods and Xba I endonuclease were utilized to evaluate
genotypic patterns among the isolates and subsequently
group them into pulsed-field types (PFTs). Clonality was
assessed using the commercial software BioNumerics
(Applied Maths, Inc., Austin, TX) and defined by 85 %
similarity. Multiplex PCRs were performed to determine
their phylogenetic groups (A, B1, B2, C, D, E, F, Clade I)
per the revised Clermont method [14].
Table 1 Overall demographics and exposures during international
travel, number (%) of subjects (N= 58)
Male gender 24 (41)
Age, median (minimum-maximum) 64 (15–82)
Regiona




South America 2 (3)
North America 2 (3)
Purpose of travela
Vacation 43 (74)
Visiting friends and relatives 10 (17)
Other (missionary/volunteer) 5 (9)
Deployment and military duty 4 (7)
School 1 (2)





Friends and relatives 13 (22)
Group livingb 10 (17)
Boat/cruise 7 (12)
Local water ingestion during travel 27 (47)
Water exposures during travel 20 (34)
Antimicrobial exposure since enrollment 23 (40)




Antibiotics for traveler’s diarrhea since enrollment 3 (5)
Ciprofloxacin 2 (3)
Erythromycin 1 (2)





Unknown antibiotic 1 (2)
Illness since enrollment 13 (22)
Duration of illness, median (minimum-maximum) 4 days (1–27)
aPercentages greater than 100 as someone can be counted more than once
based upon region of travel or living conditions
bGroup living included barracks, dorms, or kibbutz
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Statistical analysis
The McNemar test was used to compare overall rates of
pre- and post-travel ESBL and resistant gram-negative bac-
teria, S. aureus, and resistance to select antibacterial agents.
Risk factor analysis was evaluated with χ2 and Fisher’s exact
test (when expected cell counts were less than 5) for cat-
egorical variables and Mann–Whitney U for continuous
variables. A p value of <0.05 was used as a significant cutoff.
Statistical analyses were performed using SPSS software
(IBM® SPSS® Statistics Version 19, Chicago, Illinois).
Results
Demographics
Of 58 participants, the majority were female and median
age was 64 (Table 1). Pre- and post-travel swabs were ob-
tained a median of ten and seven days before and after
travel, respectively. The primary regions of travel were
Mexico, the Caribbean, and Central America; Asia; and
Africa with a median duration of travel of 12 days. The
most frequent purpose of travel was vacation followed by
visiting friends and relatives.
E. coli colonization pre- and post-travel
Fifty-two of 58 subjects had E. coli identified from either
pre- or post-travel swabs and 36 had E. coli identified from
both pre- and post-travel swabs (serial isolation) (Table 2).
Multiple other notable gram-negative organisms were also
isolated during screening, but none were associated with
MDR or ESBL-production.
While no patients were colonized with ESBL-producing
E.coli pre-travel, five (9 %) participants post-travel were
colonized perirectally (p = 0.06) (Table 3). The five ESBL-
producing E.coli represented four different phylo-groups
including C, E, F, with two isolates from group A. None of
the post-travel ESBL-producing E.coli phylo-groups
matched those from non-ESBL E.coli pre-travel isolates
from the same subjects. The ESBL-producing E.coli iso-
lates were all unrelated to each other and to the pre-travel
isolates from the same subjects by PFGE. There was a
trend towards increased rates of ESBL-producing E.coli
colonization in subjects who described their purpose of
travel as missionary/volunteer (p = 0.05). While 40 % of
those with ESBL-producing E. coli colonization post-travel
reported an episode of traveler’s diarrhea compared to
only 9 % of those without ESBL-producing E. coli
colonization post-travel, the results did not reach statis-
tical significance (p = 0.1). There were no other significant
associations between exposure risks and new ESBL-
producing E.coli colonization after international travel.
Antimicrobial resistance in gram-negative organisms after
travel
The ESBL-producing E.coli were universally resistant to
tetracycline, trimethoprim-sulfamethoxazole (TMP/SMX),
and cefazolin. Forty percent were also resistant to cip-
rofloxacin and gentamicin. Decreased antimicrobial
susceptibility post-travel was not unique to ESBL-
producing E.coli. Of 36 participants colonized with E. coli
pre- and post-travel, new resistance was detected to
TMP/SMX in 42 % of isolates (p < 0.01), tetracycline
in 44 % (p < 0.01), ampicillin-sulbactam in 33 % (p = 0.09),
cefazolin in 19 %, ciprofloxacin in 17 %, and gentami-
cin in 14 % of isolates after travel. While new genta-
micin resistance was not significantly increased after
travel, type of living conditions was associated with new
gentamicin resistance (p = 0.01). This was primarily re-
lated to staying with friends and relatives (VFR) as 80 % of
subjects with new gentamicin resistance reported this
exposure compared to seven percent without new genta-
micin resistance (p < 0.01). Similarly, 67 % of subjects with
new ciprofloxacin resistance reported VFR during travel
compared to seven percent without new ciprofloxacin
resistance (p < 0.01). There was also a trend toward
new TMP/SMX resistance in subjects who reported
VFR during travel with 33 % new resistance compared
to five percent of those with unchanged TMP/SMX sus-
ceptibility (p = 0.06). New TMP/SMX resistance was also
noted in 47 % of those who reported illness during travel





Anatomic site of isolate recovery
Nares Oropharynx Groin Perirectal
Escherichia coli 52 105 2 3 13 87
Staphylococcus aureus 20 50 23 19 5 3
Klebsiella species 21 22 0 6 1 15
Enterobacter species 9 12 2 5 1 4
Citrobacter species 8 14 5 1 2 6
Proteus species 8 13 0 0 2 11
Morganella morganii 6 6 0 0 3 3
Pseudomonas aeruginosa 5 6 0 3 3 0
Stenotrophomonas maltophilia 4 5 0 1 1 3
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compared to 14 % of those without illness since enroll-
ment (p = 0.06).
In contrast to the risk for new acquisition of resistance,
several factors associated with decreased rates of post-
travel resistance were identified. Thirty-three percent of
those without change in TMP/SMX resistance reported
staying in group housing (including barracks, dorms, or
kibbutz) versus no subjects with new TMP/SMX resist-
ance (p < 0.01). Similarly, 35 % of subjects without in-
creased tetracycline resistance reported group housing
during travel, compared to none with new resistance
(p < 0.01). Sixty-five percent of those without increased
tetracycline resistance compared to 25 % of those with
new tetracycline resistance (p = 0.02) and 63 % of those
without change in ampicillin-sulbactam susceptibility
versus 17 % with new ampicillin-sulbactam resistance re-
ported local water ingestion (p = 0.01). Interestingly, all
pre- and post-travel E. coli, including ESBL-producing
E.coli, were susceptible to nitrofurantoin.
The remaining gram-negative bacterial isolates were not
isolated with enough frequency to perform analysis, but in
general, were susceptible to a broad range of antimicrobial
agents. Of the subjects with evidence of persistent
colonization, one subject had serial isolation of Klebsi-
ella pneumoniae without increased resistance. Of the
two subjects with serial Citrobacter spp. and three with
Proteus spp. colonization, only one had decreased sus-
ceptibility to nitrofurantoin and another to piperacillin-
tazobactam post-travel, respectively. No subjects had
serial isolation of other gram-negative organisms.
S. aureus bacterial colonization pre- and post-travel
No participants were colonized with MRSA pre- or
post-travel (Table 4). Twenty subjects had MSSA
colonization during the study, with no significant differ-
ence between pre- and post-travel (p = 0.51). Of those
with MSSA colonization, it was detected on oropharyn-
geal screening only in 18 % of pre-travel subjects and
36 % of post-travel subjects. No risk factors were identi-
fied for change in MSSA colonization (Table 5). MSSA
isolates were universally susceptible to doxycycline, min-
ocycline, and rifampin. Only two subjects were colonized
with MSSA isolates resistant to clindamycin and TMP/
SMX, three to tetracycline, and one to moxifloxacin. No
new resistance of colonizing MSSA strains was noted on
post-travel screening.
Discussion
To further elucidate the risk factors associated with pre-
injury colonization with MDR gram-negative organisms in
our deployed population, we first sought to evaluate the
risk factors associated with MDR organism colonization
in international travelers. Within this prospective pilot
study, we determined that international travel was
Table 3 Demographic characteristics of subjects with and
without ESBL-producing E. coli acquisition during travel, number




E. coli (n = 5)
Male gender 23 (43) 1 (20)
Age, median (minimum-maximum) 63 (15–82) 67 (58–81)
Regiona
Mexico, Caribbean, & Central
America
17 (32) 1 (20)
Asia 15 (28) 2 (40)
Africa 15 (28) 1 (20)
Europe 5 (9) 0
South America 1 (2) 1 (20)
North America 2 (4) 0
Purpose of travela
Vacation 40 (76) 3 (60)
Visiting friends and relatives 10 (19) 0
Other (missionary/volunteer)* 3 (6) 2 (40)
Deployment and military duty 4 (8) 0
School 1 (2) 0
Duration of travel, median
(minimum-maximum)
12 (6–105) 11 (7–16)
Living conditionsa
Hotel 33 (62) 3 (60)
Friends and relatives 12 (23) 1 (20)
Group livingb 9 (17) 1 (20)
Boat/cruise 7 (13) 0
Local water ingestion during travel 26 (49) 1 (20)
Water exposures during travel 19 (36) 1 (20)
Antibiotic exposure since enrollment 20 (38) 3 (60)
Malaria chemoprophylaxis 19 (36) 3 (60)
Atovaquone/Proguanil 14 (26) 3 (60)
Doxycycline 3 (6) 0
Chloroquine 2 (4) 0
Antibiotics for traveler’s diarrhea
since enrollment
2 (4) 1 (20)
Ciprofloxacin 1 (2) 1 (20)
Erythromycin 1 (2) 0
Systemic antibiotics for other
indications since enrollment
2 (4) 1 (20)
Azithromycin 1 (2) 0
Cephalexin 1 (2) 0
Unknown antibiotic 0 1 (20)
Illness since enrollment 11 (21) 2 (40)
Duration of illness, median
(minimum-maximum)
4 (1–27) 5 (2–8)
aPercentages greater than 100 as someone can be counted more than once
based upon region of travel or living conditions
bGroup living included barracks, dorms, or kibbutz
*p = 0.05
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associated with a trend towards increased rates of ESBL-
producing E.coli colonization. Because of small numbers,
no individual risk factors for ESBL-producing E.coli
colonization acquisition within travel could be deter-
mined. However there were multiple risk factors, as well
as protective factors, for acquisition of individual drug
resistance within serial E. coli isolates.
Prior studies have identified international travel as a risk
factor for ESBL-producing E.coli colonization, but have
largely been performed in cohorts outside of the United
States [1, 3, 5, 15–17]. Similar to the only prior prospect-
ive study of pre- and post-travel ESBL-producing Entero-
bacteriaceae colonization within an American cohort
(based out of New York City), the only ESBL-producing
Enterobacteriaceae isolated was E. coli. Within the New
York City based cohort ESBL-producing E.coli
colonization increased from 2.5 % pre- travel to 25 %
post-travel [2]. Similar post-travel rates were noted within
European and Canadian travelers [1, 3, 9, 15]. This is in
comparison to the markedly lower rates of 0 % pre- and
9 % post-travel ESBL-producing E.coli noted within this
study. Notably, the European and New York City based
cohorts all had a higher proportion of subjects traveling to
Asia and Africa, which have been shown to be areas
with higher risk for ESBL-producing Enterobacteriaceae
acquisition [1–3, 15]. Also notable, the study based out
of New York City had a longer duration of international
travel (median 21 days compared to 12 days within our
cohort) [2].
Co-resistance to other antimicrobials is common with
ESBL-producing E.coli. All ESBL-producing E.coli isolates
were resistant to tetracycline, TMP/SMX, and cefazolin,
higher than rates reported in evaluation of ESBL-
producing E.coli domestically [18]. Within our post-travel
ESBL-producing E.coli isolates, similar to prior studies in
European travelers, there was 40 % co-resistance to cipro-
floxacin and gentamicin [1, 15, 16]. Reassuringly, all E. coli
isolates remained susceptible to nitrofurantoin as data
indicates that fecal flora serve as the initial source of
uropathogenic E. coli [1, 19].
While international travel has consistently been shown
to be associated with antimicrobial resistance acquisition,
few specific risk factors associated with international travel
have been identified. In fact, no prior studies have exam-
ined risk factors for ESBL-producing E.coli acquisition
particular to travel within an American cohort. Prior stud-
ies from European and Canadian cohorts have shown lo-
cation of travel to be a significant risk factor (including
South and East Asia, the Indian subcontinent, Middle
East, and Africa) [1, 3, 7, 15, 16]. A recent study also
revealed the United States as a risk factor for ESBL-
producing E. coli colonization after international travel for
the first time [20]. This emphasizes the point that local
resistance rates play a major role in the attributable risk of
resistance acquisition of travelers. Other risk factors iden-
tified within specific cohorts include development of
gastroenteritis or other gastrointestinal symptoms during
travel, traveler’s diarrhea, antimicrobial exposure, and
older age [1, 9, 16]. Interestingly, within a Swedish cohort,
all three travelers who were treated with ciprofloxacin for
gastroenteritis acquired ESBL-producing E.coli on post-
travel evaluation, compared to one of two subjects in our
cohort [1]. As the overall post-travel ESBL-producing
E.coli rate within our cohort was low, individual risk fac-
tors did not reach statistical significance. There was a
trend towards those who described their purpose of travel
as missionary/volunteer as having a higher rate of ESBL-
producing E.coli post-travel.
Within this cohort, the ESBL-producing E.coli were
from four distinct phylo-groups, none of which were iden-
tified as the dominant B2 phylo-group which has been as-
sociated with the global ST131 clone. A Canadian study of
31 post-travel ESBL-producing E.coli isolates revealed 10
were of the B2 phylo-group (8 of which were ST131
clones), 11 phylo-group A, 2 B1, and 8 phylo-group D [3].
Another study of 83 French soldiers following evacuation
from overseas identified 11 ESBL-producing E. coli, of
which eight were from the B2 and D phylo-types and
three from the commensal phylo-groups A and B1 [21].
Prior studies have shown that there is a higher rate











Acquisition or Persistence of MSSA colonization
between Pre- and Post-travel
Subjects 20 (35) 17 (29) 14 (24) 0.508 6 without persistent isolation, 3 new acquisitions
(11 persistent)
Nares 14 (24) 14 (24) 9 (16) 0.06 5 without persistent isolation, 0 new acquisitions
(9 persistent)
Oropharynx 14 (24) 9 (16) 10 (17) 1.00 4 without persistent isolation, 5 new acquisitions
(5 persistent)
Groin 5 (9) 4 (7) 1 (2) 0.38 4 without persistent isolation, 1 new acquisitions
(0 persistent)
Perirectal 3 (5) 2 (3) 1 (2) 1.00 2 without persistent isolation, 1 new acquisitions
(0 persistent)
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of persistent colonization, traveler’s diarrhea, and ex-
traintestinal infections with the more virulent B2 and D
phylo-groups compared with commensal E. coli phylo-
groups [14, 17, 19, 22–24]. It should be noted that these
studies were not performed with the recently revised
Clermont E. coli phylo-typing method which was used for
this study which identifies eight phylo-groups rather than
four (though likely does not affect isolates previously
assigned to B1 and B2 phylo-groups) [14]. A recent study
evaluating UTI-associated E. coli isolates with the revised
Clermont method revealed a more heterogeneous sample
than previously thought with only 56 % of the isolates be-
longing to B2 and D phylo-groups and 32 % of the urine
isolates from lineages A, B1, and E [25]. The fact that
post-travel ESBL-producing E.coli isolates were unrelated
to pre-travel isolates in the four patients with serial E. coli
isolation could represent new strain acquisition, or poly-
microbial colonization which was not captured by the
choice of single isolates for testing (though morphologic-
ally distinct appearing colonies were evaluated).
Similar to prior studies, there was a significant decrease
in antimicrobial susceptibility of E. coli isolates post-travel
[26–28]. Among E. coli isolates, there was a statistically
significant decrease in TMP/SMX and tetracycline suscep-
tibilities, as well as a trend toward decreased ampicillin-
sulbactam susceptibility. Prior studies have shown similar
rates of TMP/SMX resistance post-travel [26, 27]. Visiting
friends and relatives was associated with increased cipro-
floxacin and gentamicin resistance during travel. This is of
particular concern as ciprofloxacin and gentamicin resist-
ance has been associated with prolonged carriage in prior
studies of travelers, with up to ten percent of participants
still harboring ciprofloxacin or gentamicin resistance at
six months following travel [17].
Interestingly, both group housing and local water inges-
tion during travel were associated with decreased acquisi-
tion of antimicrobial resistance during travel, particularly
to ampicillin-sulbactam and tetracycline. Similar findings
were noted in a study by Kennedy and Collignon who re-
ported that returning without resistant E. coli was statisti-
cally associated with consumption of water that was not
bottled or boiled [26].
Unlike a prior study of US- and Afghanistan-based mili-
tary personnel, no MRSA was detected at any point [29].
As in prior studies, recovery of S. aureus was increased by
extra-nares screening [30, 31]. Eighteen percent of pre-
travel and 36 % of post-travel S. aureus isolates were
recovered from only the oropharynx. Also differing from
the prior military population where the US-based
personnel had higher rates of oropharyngeal colonization,
rates of oropharyngeal colonization increased from 53 %
pre-travel to 72 % post-travel within our cohort [29].
Limitations of our study include the small cohort size
and subsequent low rate of ESBL-producing E. coli
Table 5 Demographic characteristics of subjects with and without
change in MSSA colonization, number (%) of subjects (N= 58) c
No change in
MSSA (n = 49)
Change in
MSSA (n = 9)
Male gender 18 (37) 6 (67)
Age, median (minimum-maximum) 64 (15–82) 55 (18–81)
Regiona
Mexico, Caribbean, & Central
America
16 (33) 2 (22)
Asia 14 (29) 3 (33)
Africa 14 (29) 2 (22)
Europe 4 (8) 1 (11)
South America 1 (2) 1 (11)
North America 2 (4) 0
Purpose of travela
Vacation 37 (76) 6 (67)
Visiting friends and relatives 7 (14) 3 (33)
Other (missionary/volunteer) 5 (10) 0
Deployment and military duty 3 (6) 1 (11)
School 1 (2) 0
Duration of travel, median
(minimum-maximum)
12 (6–105) 12 (8–42)
Living conditionsa
Hotel 31 (63) 5 (56)
Friends and relatives 10 (20) 3 (33)
Group livingb 10 (20) 0
Boat/cruise 6 (12) 1 (11)
Local water ingestion during travel 24 (49) 3 (33)
Water exposures during travel 18 (37) 2 (22)
Antibiotic exposure since enrollment 18 (37) 5 (56)
Malaria chemoprophylaxis 17 (35) 5 (56)
Atovaquone/Proguanil 15 (31) 2 (22)
Doxycycline 1 (2) 2 (22)
Chloroquine 1 (2) 1 (11)
Antibiotics for traveler’s diarrhea
since enrollment
3 (6) 0
Ciprofloxacin 2 (4) 0
Erythromycin 1 (2) 0
Systemic antibiotics for other
indications since enrollment
3 (6) 0
Azithromycin 1 (2) 0
Cephalexin 1 (2) 0
Unknown antibiotic 1 (2) 0
Illness since enrollment 13 (27) 0
Duration of illness, median
(minimum-maximum)
4 (1–27) n/a
aPercentages greater than 100 as someone can be counted more than once
based upon region of travel or living conditions
bGroup living included barracks, dorms, or kibbutz
cNo statistically significant differences identified between the two groups
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colonization. Additionally, there were relatively few trav-
elers to previously identified high risk regions for resist-
ance acquisition. These factors led to decreased power to
detect individual risk factors for antimicrobial resistance
acquisition. Because the median age of our study popula-
tion is 64 years, this limits applicability of these findings to
our active duty military population, but does make it more
generalizable to the average international traveler. Screen-
ing for ESBL-producing E. coli colonization was per-
formed with perirectal swabs rather than stool culture, the
gold standard, which may have decreased yield. However,
Lautenbach et al. have shown the sensitivity of perirectal
swabs compared to stool samples for identification of re-
sistant gram-negative bacilli to be 90 %. They also showed
that perirectal swabs were in complete agreement with
rectal swabs and were most likely to be falsely negative
when the burden of resistant gram-negatives within stool
culture was very low [32]. Use of rectal swabs has been
used successfully in similar prior studies [15].
Conclusion
Overall, our findings support those seen in prior studies,
with increased rates of antimicrobial resistance following
international travel. Visiting friends and relatives was
associated with acquisition of resistance to various anti-
microbials including ciprofloxacin, one of the first line
antimicrobials for treating E. coli infections. While, trav-
eler’s diarrhea has been shown to not only be associated
with an average 24-h period of disability, but also long-
term complications including persistent or intermittent
gastrointestinal symptoms in a minority of travelers (in-
cluding subsequent diagnosis of irritable bowel syn-
drome in between five and ten percent), its occurrence
as well as treatment has been associated with increased
risk of antimicrobial resistance acquisition [1, 9, 16, 33].
Further elucidation of risks for antimicrobial resistance
acquisition while traveling will better enable providers
to counsel their patients regarding risks of travel. It will
also allow providers to further balance the risks and
benefits of empiric treatment of traveler’s diarrhea with
antimicrobials [34]. Reassuringly, our rates of ESBL-
producing E.coli acquisition were significantly lower
than those seen in other studies of international trav-
elers. Larger, prospective studies are needed to further
define individual risk factors particular to travel which
are associated with ESBL-producing Enterobacteriaceae
acquisition.
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